Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of $0.20, $0.06 better than the analyst estimate of $0.14. Revenue for the quarter came in at $250.4 million versus the consensus estimate of $248.6 million.

GUIDANCE:

Acadia Pharma sees FY2024 revenue of $940-960 million, versus the consensus of $952.5 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.